Q4 2021 Results
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
TafinlarⓇ+MekinistⓇ, PromactaⓇ/Revolade® and JakaviⓇ with
continued double-digit growth
Tafinlar®+MekinistⓇ
USD m, % cc
Ex-US
US
PromactaⓇ/Revolade®
USD m, % cc
Ex-US
US
JakaviⓇ
USD m, % cc
+12%
+14%
+12%
518
471
458
408
376
408
272
248
297
259
223
149
161
Q4 2021
246
Q4 2021
Q4 2021
Q4 2020
Continued growth and leadership in
both adjuvant and metastatic
BRAF+ melanoma and lung
Q4 2020
Double-digit growth in all regions driven by
sustained efficacy, oral convenience and
non-immunosuppressive profile
Q4 2020
Strong growth driven by earlier usage in
myelofibrosis and polycythemia vera;
further uptake expected from GVHD launches
GVHD Graft-versus-host disease
35 Investor Relations | Q4 2021 Results
1 NOVARTIS | Reimagining MedicineView entire presentation